Deltec Asset Management LLC Buys 21,800 Shares of Boston Scientific Corporation $BSX

Deltec Asset Management LLC raised its stake in Boston Scientific Corporation (NYSE:BSX) by 335.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 28,300 shares of the medical equipment provider’s stock after purchasing an additional 21,800 shares during the quarter. Deltec Asset Management LLC’s holdings in Boston Scientific were worth $3,040,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. HM Payson & Co. boosted its position in Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock worth $694,000 after purchasing an additional 98 shares during the last quarter. Park Square Financial Group LLC boosted its position in Boston Scientific by 5.2% in the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock worth $208,000 after purchasing an additional 103 shares during the last quarter. HHM Wealth Advisors LLC boosted its position in Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock worth $89,000 after purchasing an additional 103 shares during the last quarter. Rise Advisors LLC boosted its position in Boston Scientific by 13.9% in the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 103 shares during the last quarter. Finally, Forum Financial Management LP boosted its position in Boston Scientific by 0.8% in the first quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider’s stock worth $1,357,000 after purchasing an additional 112 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. The trade was a 17.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 124,214 shares of company stock worth $13,048,957. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Performance

NYSE BSX opened at $97.55 on Wednesday. The company has a market cap of $144.54 billion, a P/E ratio of 58.07, a P/E/G ratio of 2.34 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The business’s 50 day moving average price is $103.53 and its 200-day moving average price is $102.13. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company’s revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

BSX has been the topic of several research reports. Wells Fargo & Company raised their target price on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Barclays raised their price objective on Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Royal Bank Of Canada reissued an “outperform” rating and set a $125.00 target price on shares of Boston Scientific in a research note on Monday. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $118.38.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.